Relationship of a dominant advanced glycation end product, serum carboxymethyl-lysine, and abnormal glucose metabolism in adults: The baltimore longitudinal study of aging

[1]  G. Wolf,et al.  Advanced glycation end‐products and the kidney , 2010, European journal of clinical investigation.

[2]  S. Bandinelli,et al.  Plasma Carboxymethyl‐Lysine, an Advanced Glycation End Product, and All‐Cause and Cardiovascular Disease Mortality in Older Community‐Dwelling Adults , 2009, Journal of the American Geriatrics Society.

[3]  S. Bandinelli,et al.  Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults , 2009, European journal of nutrition.

[4]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[5]  G. Striker,et al.  Glycotoxins in the diet promote diabetes and diabetic complications , 2007, Current diabetes reports.

[6]  Bernd Stratmann,et al.  Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. , 2007, The American journal of clinical nutrition.

[7]  L. Ferrucci,et al.  Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. , 2007, The journals of gerontology. Series A, Biological sciences and medical sciences.

[8]  L. Hunsicker,et al.  The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension , 2006 .

[9]  B. Wolffenbuttel,et al.  Time course of specific AGEs during optimised glycaemic control in type 2 diabetes. , 2004, The Netherlands journal of medicine.

[10]  J. Hwang,et al.  Clinical implications of Nε‐(carboxymethyl)lysine, advanced glycation end product, in children and adolescents with type 1 diabetes , 2005, Diabetes, obesity & metabolism.

[11]  H. Stopper,et al.  Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients , 2005, Clinical chemistry and laboratory medicine.

[12]  K. Hirata,et al.  Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes. , 2004, Endocrine journal.

[13]  R. de Caterina,et al.  Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. , 2004, Cardiovascular research.

[14]  J. Uribarri,et al.  Advanced glycoxidation end products in commonly consumed foods. , 2004, Journal of the American Dietetic Association.

[15]  G. Lang,et al.  Elevated serum levels of Nε-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema , 2004, Diabetologia.

[16]  C. Stehouwer,et al.  Increased accumulation of the glycoxidation product Nepsilon-(carboxymethyl)lysine in hearts of diabetic patients: generation and characterisation of a monoclonal anti-CML antibody. , 2004, Biochimica et biophysica acta.

[17]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[18]  J. Uribarri,et al.  Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  P. Sharp,et al.  Serum levels of low molecular weight advanced glycation end products in diabetic subjects , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[20]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[21]  Hiroshi Yamamoto,et al.  Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. , 2003, Journal of diabetes and its complications.

[22]  R. Bucala,et al.  Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.

[23]  R. Bucala,et al.  Endothelial dysfunction and advanced glycation end products in type 2 diabetes mellitus , 2002 .

[24]  R. Leach,et al.  The worldwide obesity epidemic. , 2001, Obesity research.

[25]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[26]  K. Birkeland,et al.  Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. , 1999, Diabetes care.

[27]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[28]  J. Clausen,et al.  The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. , 1998, Diabetes care.

[29]  T. Yasuda,et al.  Increased serum levels of advanced glycation end-products and diabetic complications. , 1998, Diabetes research and clinical practice.

[30]  R. Bucala,et al.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[32]  I. Rossman,et al.  Normal Human Aging: The Baltimore Longitudinal Study of Aging , 1986 .

[33]  David Arenberg,et al.  Normal Human Aging: The Baltimore Longitudinal Study on Aging , 1984 .

[34]  J. Albers,et al.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.

[35]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.